Key result
Pretreatment with Angiotensin III improved postischemic left ventricular pressures and decreased infarct size in rat hearts subjected to ischemia/reperfusion injury.
Why the study?
Does Angiotensin III improve postischemic left ventricular function and reduce infarct size in rat hearts subjected to ischemia/reperfusion injury?
Does Angiotensin III improve postischemic left ventricular function and reduce infarct size in rat hearts subjected to ischemia/reperfusion injury?
Angiotensin III exerts cardioprotective effects against ischemia/reperfusion injury in rat hearts, likely via AT2R and KATP channels activating antioxidant and antiapoptotic pathways.
Angiotensin III effects in rat hearts should not change practice; leaves open translation to human ischemia/reperfusion injury.
Angiotensin III (Ang III) has similar effects on blood pressure and aldosterone secretion as Ang II, but cardioprotective effects are also proposed. In this study, we investigated whether Ang III protects the heart against ischemia/reperfusion (I/R) injury. After sacrificing Sprague-Dawley rats, the hearts were perfused with Krebs-Henseleit buffer for a 20 min preischemic period with and without Ang III followed by 20-min global ischemia and 50-min reperfusion. Pretreatment with Ang III (1 μmol/L) improved an increased postischemic left ventricular end-diastolic pressure (LVEDP) and a decreased postischemic left ventricular developed pressure (LVDP) induced by reperfusion compared to untreated hearts. Ang III markedly decreased infarct size and lactate dehydrogenase levels in effluent during reperfusion. Ang III increased coronary flow and the concentrations of atrial natriuretic peptide in coronary effluent during reperfusion. Pretreatment with Ang II type 2 receptor (AT2R) antagonist or ATP-sensitive K(+) channel (KATP) blocker for 15 min before ischemia attenuated the improvement of LVEDP, LVDP, and ±dP/dt induced by Ang III. Ang III treatment increased Mn-superoxide dismutase, catalase, and heme oxygenase-1 protein levels, which was attenuated by pretreatment with AT2R antagonist or KATP blocker. Ang III treatment also decreased Bax, caspase-3, and caspase-9 protein levels, and increased Bcl-2 protein level, which were attenuated by pretreatment with AT2R antagonist or KATP blocker. These results suggest that the cardioprotective effects of Ang III against I/R injury may be partly related to activating antioxidant and antiapoptotic enzymes via AT2R and KATP channels.
No takes yet. Share an insight, caveat, or question.
Park et al. (2013) studied Ischemia/reperfusion (I/R) injury. Angiotensin III vs. Untreated hearts was evaluated on Left ventricular end-diastolic pressure (LVEDP) and left ventricular developed pressure (LVDP). Pretreatment with Angiotensin III improved postischemic left ventricular pressures and decreased infarct size in rat hearts subjected to ischemia/reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: